These data reconcile the coincident inflammatory cytokinemia and functional immunosuppression induced by COVID-19 and suggest modulation of STAT3 as a potential therapeutic avenue to restore T cell function during severe COVID-19. The gene discussed is STAT3; the disease is COVID-19.